Histopathological ultrastaging of mesocolic lymph nodes after colon cancer resection: A systematic review and
Bart Ct van de Laar1, Daan J Sikkenk1, Gursah Kats-Ugurlu2
1Department of Surgery, University Medical Center Groningen, Hanzeplein 1, Groningen 9713 GZ, the Netherlands; Department of Surgery, Meander Medical Center, Maatweg 3, Amersfoort 3813 TZ, the Netherlands.
Background:
In colon cancer (CC), lymph node (LN) (micro)metastases determine the need for adjuvant chemotherapy. Routine single-section hematoxylin and eosin (H&E) may miss (micro)metastases, resulting in understaging. Histopathological ultrastaging using serial sectioning (SS) and immunohistochemistry (IHC) can improve metastasis detection, for example in the context of organ-preserving surgery using a sentinel lymph node (SLN) procedure. This review evaluates SS and IHC for detecting LN (micro)metastases and aims to identify the ultrastaging method with the highest detection rate. Isolated tumor cells were analyzed separately and were not considered indicative of nodal upstaging.
Methods:
PubMed, Embase, and the Cochrane Library were searched. Studies were included if they evaluated histopathological ultrastaging alongside routine H&E in patients with CC and reported results separately. Risk of bias was assessed using QUADAS-2. Pooled proportions were calculated using random-effects models.
Results:
Thirty studies (n = 1822 patients) using SS and IHC were included. In SLN studies (n = 23), 21 % (95 % CI: 12-31 %) of 1070 patients had LN (micro)metastases. Among node-positive patients, 25 % (95 % CI: 6.0-50 %) were identified only by SLN ultrastaging. The absolute benefit of ultrastaging in the total cohort was small, 3.0 % (95 % CI: 1.0-5.0 %), with moderate heterogeneity. In non-SLN studies (n = 7), ultrastaging of all LNs upstaged 6.0 % (95 % CI: 2.0-13 %) of 752 patients, with high heterogeneity. IHC identified only one additional micrometastasis beyond SS. Protocol heterogeneity was considerable.
Conclusion:
Histopathological ultrastaging detects (micro)metastases, but its clinical impact on adjuvant chemotherapy benefit remains uncertain. Protocol standardization is needed, and the added value of IHC beyond SS appears minimal.
More Related Videos
12:45Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025